Innovation in pharmaceuticals, medical devices, diagnostic and digital health technologies has transformed the way we deliver and manage treatments and organize healthcare systems. The challenges in uptake of integrated technologies may hinder patient access to new treatment options, potentially affecting patient outcomes and stifling innovation and commercial success in the European life sciences sector. To better understand the factors that can limit access to transformative technologies, CRA consultants, in collaboration with members of the American Chamber of Commerce to the European Union (AmCham EU) recently analyzed these challenges and opportunities.
To access the full article, click the link below.
Navigating Payer Challenges in Rare Disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...